{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T08:29:03Z","timestamp":1793521743727,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T00:00:00Z","timestamp":1740528000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim. Care Respir. Med."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Inhaled corticosteroids (ICS) plus long-acting \u03b2<jats:sub>2<\/jats:sub>-agonists (LABA) are recommended for maintenance-only or maintenance and reliever therapy (MART) in patients with asthma. However, real-world data on ICS\/LABA as maintenance-only or MART are limited. This study characterized clinical, economic, and humanistic burdens of asthma in Canada, China, Europe, Japan, and the US, using data collected from patients and physicians via a cross-sectional survey (Asthma Disease Specific Programme). Patients were \u226518 years of age with physician-confirmed asthma and receiving fixed-dose ICS\/LABA for \u22653 months. Mean physician-reported symptom-free days over the past 30 days ranged from 10.1\u201320.6 days, and 31.5\u201334.6% of ICS\/LABA users self-reported not well-controlled asthma. SABA co-prescription was reported in 8.8\u201367.8% of patients. These findings highlight the continued disease burden among ICS\/LABA users, with the high level of SABA co-prescription indicating potentially inappropriate prescribing of ICS\/LABA as MART or detrimental reliance on SABA medication in addition to MART.<\/jats:p>","DOI":"10.1038\/s41533-024-00402-w","type":"journal-article","created":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T06:11:31Z","timestamp":1740550291000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Burden of illness among patients with asthma prescribed inhaled corticosteroids\/long-acting \u03b22-agonists"],"prefix":"10.1038","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8523-0419","authenticated-orcid":false,"given":"Shiyuan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandrosz","family":"Czira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Harley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieran J.","family":"Rothnie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,26]]},"reference":[{"key":"402_CR1","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2023, https:\/\/ginasthma.org\/2023-gina-main-report\/ (2023)."},{"key":"402_CR2","doi-asserted-by":"publisher","first-page":"106670","DOI":"10.1016\/j.rmed.2021.106670","volume":"191","author":"A Czira","year":"2022","unstructured":"Czira, A. et al. A systematic literature review of burden of illness in adults with uncontrolled moderate\/severe asthma. Respir. Med. 191, 106670 (2022).","journal-title":"Respir. Med."},{"key":"402_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S2213-2600(13)70012-2","volume":"1","author":"A Papi","year":"2013","unstructured":"Papi, A. et al. Beclometasone-formoterol as maintenance and reliever treatment in patients with asthma: a double-blind, randomised controlled trial. Lancet Respir. Med. 1, 23\u201331 (2013).","journal-title":"Lancet Respir. Med."},{"key":"402_CR4","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/S2213-2600(13)70007-9","volume":"1","author":"M Patel","year":"2013","unstructured":"Patel, M. et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir. Med. 1, 32\u201342 (2013).","journal-title":"Lancet Respir. Med."},{"key":"402_CR5","doi-asserted-by":"publisher","first-page":"00140","DOI":"10.1183\/23120541.00140-2022","volume":"8","author":"SG Noorduyn","year":"2022","unstructured":"Noorduyn, S. G. et al. SABA use as an indicator for asthma exacerbation risk: an observational cohort study (SABINA Canada). ERJ Open Res. 8, 00140\u201302022 (2022).","journal-title":"ERJ Open Res."},{"key":"402_CR6","first-page":"e25465","volume":"14","author":"S Guyton","year":"2022","unstructured":"Guyton, S. & Jackson, T. Asthma control and medication reliance among asthmatics in a general practice setting\u2014a questionnaire based study. Cureus 14, e25465 (2022).","journal-title":"Cureus"},{"key":"402_CR7","doi-asserted-by":"publisher","first-page":"2638","DOI":"10.1016\/j.jaip.2022.06.009","volume":"10","author":"C Kim","year":"2022","unstructured":"Kim, C. et al. Effectiveness of maintenance and reliever therapy using inhaled corticosteroid-formoterol in asthmatics. J. Allergy Clin. Immunol. Pract. 10, 2638\u20132645.e2633 (2022).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"402_CR8","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.rmed.2011.10.001","volume":"106","author":"L Allegra","year":"2012","unstructured":"Allegra, L. et al. Real-life prospective study on asthma control in Italy: cross-sectional phase results. Respir. Med. 106, 205\u2013214, https:\/\/doi.org\/10.1016\/j.rmed.2011.10.001 (2012).","journal-title":"Respir. Med."},{"key":"402_CR9","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3109\/02770900903518835","volume":"47","author":"JL Hermosa","year":"2010","unstructured":"Hermosa, J. L., Sanchez, C. B., Rubio, M. C., Minguez, M. M. & Walther, J. L. Factors associated with the control of severe asthma. J. Asthma 47, 124\u2013130 (2010).","journal-title":"J. Asthma"},{"key":"402_CR10","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1080\/02770903.2018.1455858","volume":"56","author":"J Davis","year":"2019","unstructured":"Davis, J., Trudo, F., Siddall, J. & Small, M. Burden of asthma among patients adherent to ICS\/LABA: A real-world study. J. Asthma 56, 332\u2013340 (2019).","journal-title":"J. Asthma"},{"key":"402_CR11","doi-asserted-by":"publisher","first-page":"e010352","DOI":"10.1136\/bmjopen-2015-010352","volume":"6","author":"SM Babineaux","year":"2016","unstructured":"Babineaux, S. M., Curtis, B., Holbrook, T., Milligan, G. & Piercy, J. Evidence for validity of a national physician and patient-reported, cross-sectional survey in China and UK: the Disease Specific Programme. BMJ Open 6, e010352 (2016).","journal-title":"BMJ Open"},{"key":"402_CR12","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.1185\/03007990802457040","volume":"24","author":"P Anderson","year":"2008","unstructured":"Anderson, P., Benford, M., Harris, N., Karavali, M. & Piercy, J. Real-world physician and patient behaviour across countries: disease-specific programmes\u2014a means to understand. Curr. Med Res Opin. 24, 3063\u20133072 (2008).","journal-title":"Curr. Med Res Opin."},{"key":"402_CR13","doi-asserted-by":"publisher","first-page":"353","DOI":"10.2165\/00019053-199304050-00006","volume":"4","author":"MC Reilly","year":"1993","unstructured":"Reilly, M. C., Zbrozek, A. S. & Dukes, E. M. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 4, 353\u2013365 (1993).","journal-title":"Pharmacoeconomics"},{"key":"402_CR14","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jaci.2003.09.008","volume":"113","author":"RA Nathan","year":"2004","unstructured":"Nathan, R. A. et al. Development of the asthma control test: a survey for assessing asthma control. J. Allergy Clin. Immunol. 113, 59\u201365 (2004).","journal-title":"J. Allergy Clin. Immunol."},{"key":"402_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/0895-4356(88)90138-2","volume":"41","author":"CD Jenkins","year":"1988","unstructured":"Jenkins, C. D., Stanton, B. A., Niemcryk, S. J. & Rose, R. M. A scale for the estimation of sleep problems in clinical research. J. Clin. Epidemiol. 41, 313\u2013321 (1988).","journal-title":"J. Clin. Epidemiol."},{"key":"402_CR16","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1007\/s11136-012-0322-4","volume":"22","author":"MF Janssen","year":"2013","unstructured":"Janssen, M. F. et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual. Life Res. 22, 1717\u20131727 (2013).","journal-title":"Qual. Life Res."},{"key":"402_CR17","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1080\/02770903.2017.1316394","volume":"55","author":"LK Lee","year":"2018","unstructured":"Lee, L. K., Obi, E., Paknis, B., Kavati, A. & Chipps, B. Asthma control and disease burden in patients with asthma and allergic comorbidities. J. Asthma 55, 208\u2013219 (2018).","journal-title":"J. Asthma"},{"key":"402_CR18","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.anai.2020.12.015","volume":"126","author":"J Oppenheimer","year":"2021","unstructured":"Oppenheimer, J. et al. Real-world evidence: Patient views on asthma in respiratory specialist clinics in America. Ann. Allergy Asthma Immunol. 126, 385\u2013393 e382 (2021).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"402_CR19","doi-asserted-by":"publisher","first-page":"e000534","DOI":"10.1136\/bmjresp-2019-000534","volume":"7","author":"LK Lee","year":"2020","unstructured":"Lee, L. K., Ramakrishnan, K., Safioti, G., Ariely, R. & Schatz, M. Asthma control is associated with economic outcomes, work productivity and health-related quality of life in patients with asthma. BMJ Open Respir. Res. 7, e000534 (2020).","journal-title":"BMJ Open Respir. Res."},{"key":"402_CR20","doi-asserted-by":"publisher","first-page":"106524","DOI":"10.1016\/j.rmed.2021.106524","volume":"186","author":"KR Chapman","year":"2021","unstructured":"Chapman, K. R. et al. Asthma patients' and physicians' perspectives on the burden and management of asthma. Respir. Med. 186, 106524 (2021).","journal-title":"Respir. Med."},{"key":"402_CR21","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1016\/j.jaip.2022.03.027","volume":"10","author":"I Vahatalo","year":"2022","unstructured":"Vahatalo, I. et al. Long-term use of short-acting beta(2)-agonists in patients with adult-onset asthma. J. Allergy Clin. Immunol. Pr. 10, 2074\u20132083.e2077 (2022).","journal-title":"J. Allergy Clin. Immunol. Pr."},{"key":"402_CR22","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S2213-2600(20)30389-1","volume":"9","author":"LA Lee","year":"2021","unstructured":"Lee, L. A. et al. Efficacy and safety of once-daily single-inhaler triple therapy (FF\/UMEC\/VI) versus FF\/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial. Lancet Respir. Med. 9, 69\u201384, https:\/\/doi.org\/10.1016\/S2213-2600(20)30389-1 (2021).","journal-title":"Lancet Respir. Med."},{"key":"402_CR23","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1016\/S0140-6736(19)32215-9","volume":"394","author":"JC Virchow","year":"2019","unstructured":"Virchow, J. C. et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet 394, 1737\u20131749 (2019).","journal-title":"Lancet"},{"key":"402_CR24","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/S2213-2600(20)30190-9","volume":"8","author":"HAM Kerstjens","year":"2020","unstructured":"Kerstjens, H. A. M. et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir. Med. 8, 1000\u20131012 (2020).","journal-title":"Lancet Respir. Med."},{"key":"402_CR25","doi-asserted-by":"publisher","first-page":"2101402","DOI":"10.1183\/13993003.01402-2021","volume":"59","author":"ED Bateman","year":"2022","unstructured":"Bateman, E. D. et al. Short-acting beta2-agonist prescriptions are associated with poor clinical outcomes of asthma: the multi-country, cross-sectional SABINA III study. Eur. Respir. J. 59, 2101402 (2022).","journal-title":"Eur. Respir. J."},{"key":"402_CR26","doi-asserted-by":"publisher","first-page":"1901872","DOI":"10.1183\/13993003.01872-2019","volume":"55","author":"BI Nwaru","year":"2020","unstructured":"Nwaru, B. I. et al. Overuse of short-acting beta2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme. Eur. Respir. J. 55, 1901872 (2020).","journal-title":"Eur. Respir. J."},{"key":"402_CR27","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.anai.2012.08.014","volume":"109","author":"RH Stanford","year":"2012","unstructured":"Stanford, R. H., Shah, M. B., D'Souza, A. O., Dhamane, A. D. & Schatz, M. Short-acting beta-agonist use and its ability to predict future asthma-related outcomes. Ann. Allergy Asthma Immunol. 109, 403\u2013407 (2012).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"402_CR28","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2019, https:\/\/ginasthma.org\/archived-reports\/ (2019)."},{"key":"402_CR29","unstructured":"Global Initiative for Asthma. Global Strategy for Asthma Management and Prevention 2020, https:\/\/ginasthma.org\/archived-reports\/ (2020)."}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-024-00402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-024-00402-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-024-00402-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T06:11:37Z","timestamp":1740550297000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-024-00402-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,26]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["402"],"URL":"https:\/\/doi.org\/10.1038\/s41533-024-00402-w","relation":{},"ISSN":["2055-1010"],"issn-type":[{"value":"2055-1010","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,26]]},"assertion":[{"value":"17 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.C. was an employee of GSK and held financial equities in GSK. S.Z. and K.J.R. are employees of and hold financial equities in in GSK. J.H., L.L., and M.S. are employees of Adelphi Real World, an agency that received funding from GSK to undertake this study. Trade marks are the property of their respective owners.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}